ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02470052
Recruitment Status : Active, not recruiting
First Posted : June 12, 2015
Last Update Posted : August 6, 2018
Sponsor:
Information provided by (Responsible Party):
Olympus Corporation

Brief Summary:

This is a multicenter,single-arm,open-label study designed to evaluate improvement of lung function and safety after treatment with OL-BF-001 for severe emphysema.

OL-BF-001 consists of a bronchial valve, deployment catheter, loader and airway sizing kit. A bronchial valve is a small, umbrella-shaped, one-way valve that is placed inside the airways of one lung. It is used to redirect air from the less healthy to the more healthy parts of the lung. This helps to reduce over-inflation and may improve overall lung function and quality of life for people living with emphysema.


Condition or disease Intervention/treatment Phase
Emphysema Device: OL-BF-001 Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema
Study Start Date : August 2015
Actual Primary Completion Date : April 2018
Estimated Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Emphysema

Arm Intervention/treatment
Experimental: OL-BF-001
Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
Device: OL-BF-001
Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.




Primary Outcome Measures :
  1. responder rate after deployment of valves [ Time Frame: 6months after deployment of valves ]
    definition of responder: St. George's Respiratory Questionnaire (SGRQ) improving and Pulmonary Function improving (either Forced Expiratory Volume in 1 second (FEV1) improving or Inspiratory Capacity (IC) improving)


Secondary Outcome Measures :
  1. Change in exercise capacity as measured by Six Minute Walk Test (6MWT) [ Time Frame: before deployment of valves and 6months after deployment of valves ]
  2. Change in dyspnea as measured by Baseline and Transition Dyspnea Indexes(BDI-TDI) [ Time Frame: before deployment of valves and 6months after deployment of valves ]
  3. Change in health status as measured by St. George's Respiratory Questionnaire(SGRQ) [ Time Frame: before deployment of valves and 6months after deployment of valves ]
  4. Change in dyspnea as measured by Medical Research Council, Modified (mMRC) Questionnaire [ Time Frame: before deployment of valves and 6months after deployment of valves ]
  5. Change in pulmonary function as measured by FEV1,Forced Vital Capacity(FVC),Vital Capacity(VC),Residual Volume(RV),IC,Total Lung Capacity(TLC),RV/TLC,Diffusing Capacity of the Lung for Carbon Monoxide(DLCO) [ Time Frame: before deployment of valves and 6months after deployment of valves ]
  6. Change in target lobe volume as measured by Quantitative CT (QCT) [ Time Frame: before deployment of valves and 6months after deployment of valves ]

Other Outcome Measures:
  1. Incidence of Severe and Serious Adverse Events(SAEs) whose relationship with the investigational device or the procedure cannot be ruled out [ Time Frame: before deployment of valves and 6months after deployment of valves ]
  2. Incidence of Adverse Events(AEs) whose relationship with the investigational device or the procedure cannot be ruled out [ Time Frame: before deployment of valves and 6months after deployment of valves ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is treated by maximum medical management( pharmacological therapy and nonpharmacological therapy ) for 3 months and over before screening testing and the same treatment will be conducted during the study period.
  • Subject must have severe dyspnea which is defined as a mMRC ≥ 2.
  • Subject's obstructive disease is severe as defined by following post-bronchodilator spirometry values: FEV1/FVC < 70% and 20% of predicted ≤ FEV1 < 50% of predicted
  • Subject's hyperinflation is defined by: RV/TLC ≥ 40%
  • Subject has severe emphysema and high heterogeneity defined as: a target lobe with ≥ 50% emphysema involvement and clearly different with the ipsilateral lobe, which is judged by visual assessment of thoracic CT. Lung perfusion scan is added to the assessment in principle.
  • The target lobe and ipsilateral lobe will be separated with an intact fissure. An intact fissure will be estimated visually to be ≥ 90% complete with no segmental vessels crossing from one lobe to the adjacent lobe.
  • Subject must be able to demonstrate physical ability to participate in the study by performing a 6-minute walk distance of ≥ 140 m.
  • Subject has abstained from cigarette smoking for 3 months and over before screening testing, and is able to continue to abstain throughout the study.
  • Investigator has confirmed that medical management has been conducted enough and disease state has been stable and without a COPD exacerbation for 6 weeks and over before screening testing.
  • Subject is able to participate in the study, complete the required follow-up visits, and maintain consistent nutrition and exercise habits during the study period.
  • Subject provides informed consent and is willing and able to return for all study examinations.

Exclusion Criteria:

  • Subject has a severe gas exchange abnormality in either PaCO2 or PaO2 as defined by: PCO2 > 50 mmHg, or PO2 < 50 mmHg on room air
  • Subject with DLCO < 20% of predicted
  • Subject has a BMI < 15kg/m2.
  • Subject has a risk of thromboembolism.(D-dimer value is used as a reference.)
  • Subject had COPD exacerbation which required hospitalization or administration of systemic steroids twice or more in the past 1 year prior to screening testing.
  • Subject has a history of pneumothorax twice or more in the past 1 year prior to screening testing.
  • Subject has a large amount of sputum production on a daily basis.
  • Subject has clinically apparent asthma.
  • Subject has giant bulla (> 1/3 volume in either lung. If subject has multiple bullae, the sum of them is judged whether or not > 1/3 volume in either lung. )
  • Patient has pulmonary hypertension based upon clinical evaluation.
  • Subject uses oral steroids 10 mg/day and over in prednisolone conversion.
  • Subject has comorbidities that will limit participation in the study, or follow-up during the study period.
  • Subject has a history of thoracic surgeries.
  • Subject has thoracic comorbidities (lung nodules, infections(e.g. Pulmonary tuberculosis), Interstitial pneumonia, etc.) , which are anticipated to require evaluation or intervention during the 12 months study period.
  • Subject is strongly suspected of pleural adhesions.
  • Subject has indicated Left ventricular ejection fraction(LVEF) ≤ 30% within 6 months prior to screening testing. *Subject,who had severe cardiovascular diseases in the past but can control them currently, doesn't meet this criteria.
  • Subject is judged as ineligible due to a risk of hemoptysis by investigators.
  • Subject has demonstrated unwillingness or inability to complete screening and/or baseline testing.
  • Subject has α1-antitrypsin deficiency.
  • Subject is classified as ASA Class greater than P4 or has comorbidities that could significantly increase the risk related with bronchoscopy procedure.
  • Subject has latex allergy.
  • Subject has metallic allergy.
  • Subject participated in a study of an investigational drug or device within the 30 days prior to participation in this study, or is currently participating in another clinical study.
  • Following women subjects are ineligible: Pregnant women, lactating women, potentially pregnant women, women who wish to become pregnant during the study period, women who cannot use birth control properly during the study period.
  • Subject is considered as ineligible due to other factors by investigators.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02470052


Locations
Japan
Nagoya, Aichi, Japan
Toyoake, Aichi, Japan
Sapporo, Hokkaido, Japan
Kawasaki, Kanagawa, Japan
Matsusaka, Mie, Japan
Mibu, Tochigi, Japan
Ube, Yamaguchi, Japan
Chiba, Japan
Fukuoka, Japan
Gifu, Japan
Sponsors and Collaborators
Olympus Corporation

Responsible Party: Olympus Corporation
ClinicalTrials.gov Identifier: NCT02470052     History of Changes
Other Study ID Numbers: OMSC-1401
First Posted: June 12, 2015    Key Record Dates
Last Update Posted: August 6, 2018
Last Verified: August 2018

Keywords provided by Olympus Corporation:
Endobronchial Valves
Intrabronchial Valves
Bronchial Valve
Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Bronchoscopic Lung Volume Reduction
Emphysema
Pulmonary Emphysema
Lung Diseases
Respiratory Tract Disease

Additional relevant MeSH terms:
Emphysema
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases